Dashboard
Manage Tickers

ARWRARROWHEAD PHARMACEUTICALS, ...


$ 20.01 $ -0.44 (-2.15 %)    

Tuesday, 17-Sep-2024 15:59:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 473.83 $ -2.14 (-0.45 %)
DIA $ 417.12 $ -0.26 (-0.06 %)
SPY $ 563.14 $ 0.30 (0.05 %)
TLT $ 100.82 $ -0.51 (-0.5 %)
GLD $ 237.35 $ -1.31 (-0.55 %)
$ na
$ 20.60
$ 20.00 x 192
$ 20.03 x 100
$ 19.46 - $ 20.62
$ 20.14 - $ 39.83
947,142
na
2.54B
$ 1.11
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

the-fda-granted-breakthrough-therapy-designation-to-arrowhead-pharmaceuticals-investigational-plozasiran-as-an-adjunct-to-diet-to-reduce-triglycerides-in-adults-with-familial-chylomicronemia-syndrome
The FDA Granted Breakthrough Therapy Desig...
09/10/2024 11:31:40

cantor-fitzgerald-reiterates-overweight-on-arrowhead-pharma
Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 16:56:42

Cantor Fitzgerald analyst Josh Schimmer reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Overweight.

hc-wainwright--co-reiterates-buy-on-arrowhead-pharma-maintains-60-price-target
HC Wainwright & Co. Reiterates Buy on Arro...
09/05/2024 11:04:21

HC Wainwright & Co. analyst Patrick Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 pric...

hc-wainwright--co-reiterates-buy-on-arrowhead-pharma-maintains-60-price-target
HC Wainwright & Co. Reiterates Buy on Arro...
09/03/2024 17:30:28

HC Wainwright & Co. analyst Patrick Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 pric...

arrowhead-pharmaceuticals-shares-are-trading-higher-after-the-company-announced-results-from-the-phase-3-palisade-study-of-investigational-plozasiran-in-patients-with-familial-chylomicronemia-syndrome
Arrowhead Pharmaceuticals shares are tradi...
09/03/2024 11:56:32

arrowheads-plozasiran-meets-all-primary-and-secondary-endpoints-in-phase-3-study-to-seek-fda-approval
Arrowhead's Plozasiran Meets All Primary a...
09/03/2024 07:09:14

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced results from the Phase 3 PALISADE study of investigational plozas...

arrowhead-pharmaceuticals-announced-that-it-will-present-new-phase-3-clinical-data-from-the-palisade-study-of-plozasiran-at-the-european-society-of-cardiology-congress-2024
Arrowhead Pharmaceuticals Announced That I...
08/21/2024 11:41:25

arrowhead-pharmaceuticals-to-advance-two-new-rnai-based-obesity-candidates-aro-inhbe-and-aro-alk7-into-clinical-studies-after-they-demonstrated-the-potential-to-reduce-body-weight-and-fat-mass-with-a-novel-mechanism-of-action-that-may-lead-to-improved-preservation-of-lean-muscle-mass-compared-to-currently-approved-obesity-therapies
Arrowhead Pharmaceuticals To Advance Two N...
08/14/2024 17:31:49

- Company hosting an obesity/metabolic R&D webinar today, August 14, 2024, at 2:00 pm ET as Part IV of the 2024 Summer Seri...

b-riley-securities-reiterates-buy-on-arrowhead-pharma-maintains-55-price-target
B. Riley Securities Reiterates Buy on Arro...
08/12/2024 16:04:42

B. Riley Securities analyst Mayank Mamtani reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $55 price target.

arrowhead-pharmaceuticals-announces-500m-strategic-financing-facility
Arrowhead Pharmaceuticals Announces $500M ...
08/08/2024 21:03:21

- Balance sheet strengthened with long-term, non-dilutive capital- $400 million funded at close with the potential to draw an a...

arrowhead-pharma-q3-2024-revenue-0-down-from-15825m-yoy
Arrowhead Pharma Q3 2024 Revenue $0 Down F...
08/08/2024 20:09:28

arrowhead-pharma-q3-2024-gaap-eps-138-misses-053-estimate
Arrowhead Pharma Q3 2024 GAAP EPS $(1.38) ...
08/08/2024 20:08:36

Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(1.38) per share which missed the analyst consensus estimate of $(...

hc-wainwright--co-reiterates-buy-on-arrowhead-pharma-maintains-60-price-target
HC Wainwright & Co. Reiterates Buy on Arro...
07/23/2024 17:18:47

HC Wainwright & Co. analyst Patrick Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 pric...

chardan-capital-maintains-buy-on-arrowhead-pharma-maintains-60-price-target
Chardan Capital Maintains Buy on Arrowhead...
07/17/2024 18:35:02

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 price target.

sp-global-to-rally-more-than-13-here-are-10-top-analyst-forecasts-for-friday
S&P Global To Rally More Than 13%? Here Ar...
07/05/2024 13:34:49

hc-wainwright--co-maintains-buy-on-arrowhead-pharma-lowers-price-target-to-60
HC Wainwright & Co. Maintains Buy on Arrow...
07/05/2024 10:09:29

HC Wainwright & Co. analyst Patrick Trucchio maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and lowers the price ta...

chardan-capital-maintains-buy-on-arrowhead-pharma-maintains-60-price-target
Chardan Capital Maintains Buy on Arrowhead...
06/26/2024 12:07:01

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 price target.

arrowhead-pharmaceuticals-to-advance-investigational-plozasiran-into-phase-3-capitan-cardiovascular-outcomes-trial
Arrowhead Pharmaceuticals To Advance Inves...
06/25/2024 17:58:38

– Based on results in the Phase 2 MUIR clinical study, the Phase 3 CAPITAN trial is designed to enroll patients with mixed hype...

why-arrowhead-pharmaceuticals-arwr-stock-is-seeing-blue-skies
Why Arrowhead Pharmaceuticals (ARWR) Stock...
06/24/2024 20:24:30

Arrowhead Pharmaceuticals shares are trading higher by more than 6% during Monday's session. The company announced that it ...

arrowhead-pharmaceuticals-unveils-obesity-treatment-at-ada-conference
Arrowhead Pharmaceuticals Unveils Obesity ...
06/24/2024 11:45:22

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION